Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Last Close
21.51
Oct 30 • 3:59 PM ET Dollar change+0.16 Percentage change(0.75%)
Aftermarket Close
21.48
Aftermarket • 7:30 PM ET Dollar change-0.03 Percentage change(-0.15%)
Index
RUT
Market Cap
7.49B
Enterprise Value
10.23B
Income
157.36M
Sales
3.12B
Book/sh
0.10
Cash/sh
0.39
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
0.00%
Employees
8500
IPO
Dec 19, 1995
P/E
44.89
Forward P/E
17.83
PEG
0.87
P/S
2.40
P/B
207.99
P/C
54.97
P/FCF
92.36
EV/EBITDA
15.24
EV/Sales
3.28
Quick Ratio
1.44
Current Ratio
2.20
Debt/Eq
84.55
LT Debt/Eq
80.87
Option/Short
Yes / Yes
EPS (ttm)
0.48
EPS next Y
1.21
EPS next Q
0.24
EPS this Y
24.10%
EPS next Y
17.13%
EPS next 5Y
20.57%
EPS past 3/5Y
- -18.36%
Sales past 3/5Y
10.92% 8.66%
EPS Y/Y TTM
4917.17%
Sales Y/Y TTM
9.28%
EPS Q/Q
152.81%
Sales Q/Q
9.89%
Insider Own
55.02%
Insider Trans
-0.25%
Inst Own
48.03%
Inst Trans
1.32%
ROA
4.37%
ROE
-
ROIC
5.82%
Gross Margin
39.32%
Oper. Margin
15.30%
Profit Margin
5.05%
SMA20
6.62%
SMA50
12.49%
SMA200
36.64%
Trades
Shs Outstand
319.33M
Shs Float
156.65M
52W High
21.67 -0.76%
52W Low
9.99 115.32%
Volatility
2.56% 3.04%
ATR (14)
0.63
RSI (14)
67.66
Beta
1.26
Rel Volume
0.98
Avg Volume
2.82M
Volume
2,765,641
Perf Week
5.54%
Perf Month
7.17%
Perf Quarter
14.11%
Perf Half Y
67.65%
Perf YTD
70.71%
Perf Year
115.10%
Perf 3Y
454.38%
Perf 5Y
291.80%
Perf 10Y
3.91%
Prev Close
21.35
Price
21.51
Change %
0.75%
Consensus
Strong Buy
Avg. Price Target
$23.43
Implied Upside
+8.9%
Analysts11incl. previous ratings
Rating Distribution8 Buy · 3 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 23, 2026Initiated
OPY logoOOppenheimer
Outperform$27+25.5%
Sep 09, 2026Initiated
LLeerink Partners
Outperform$23+6.9%
Apr 17, 2026Initiated
UBS logoUUBS
Buy$19-11.7%
Dec 09, 2025Initiated
BCS logoBBarclays
Overweight$15-30.3%
Jun 06, 2025Initiated
GS logoGGoldman
Buy$12-44.2%
Feb 24, 2025Upgrade
JPM logoJJP Morgan
Neutral → Overweight$9 → $12-44.2%
Sep 06, 2024Upgrade
JPM logoJJP Morgan
Underweight → Neutral$9-58.2%
Apr 07, 2021Resumed
RY logoRRBC Capital Mkts
Sector Perform$5-76.8%
Mar 08, 2021Upgrade
GS logoGGoldman
Sell → Buy$4 → $6.50-69.8%
Dec 14, 2020Upgrade
GGuggenheim
Neutral → Buy$5.50-74.4%
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BUCHI J KEVINDirectorSep 11 '26Option Exercise14.4520,445295,43095,522Sep 14 04:10 PM
Kiely JohnDirectorAug 13 '26Sale17.6450,000882,000210,252Aug 14 04:29 PM
Shah NikitaExecutive Vice PresidentAug 12 '26Sale17.51146,4032,563,517253,390Aug 13 04:22 PM
Daly Jason B.EVP, Chief Legal OfficerAug 12 '26Sale17.40210,0003,654,00035,171Aug 13 04:21 PM
Daly Jason B.EVP, Chief Legal OfficerAug 11 '26Sale17.706,613117,050245,171Aug 13 04:21 PM
JOHN KIELYDirectorAug 13 '26Proposed Sale17.5950,000879,714Aug 13 04:15 PM
NIKITA SHAHOfficerAug 12 '26Proposed Sale17.47146,4032,556,975Aug 12 04:18 PM
JASON DALYOFFICERAug 11 '26Proposed Sale17.36210,0003,646,285Aug 12 04:11 PM
BUCHI J KEVINDirectorAug 11 '26Proposed Sale17.31168,5732,917,998Aug 11 12:32 PM
Autor Deborah M.DirectorMay 11 '26Sale12.9434,819450,55893,660May 12 04:10 PM
DEBORAH AUTORDIRECTORMay 11 '26Proposed Sale12.9434,819450,416May 11 06:56 PM
Nark Ted CDirectorNov 17 '25Sale11.7250,000586,000291,029Nov 19 04:21 PM
Nark Ted CDirectorNov 17 '25Proposed Sale11.8250,000591,250Nov 17 03:06 PM
Shah NikitaExecutive Vice PresidentNov 12 '25Option Exercise2.75131,856362,604278,259Nov 14 05:13 PM
Shah NikitaExecutive Vice PresidentNov 12 '25Sale11.92131,8561,571,724146,403Nov 14 05:13 PM
NIKITA SHAHOFFICERNov 12 '25Proposed Sale11.92131,8561,571,723Nov 12 05:12 PM
Amneal Pharmaceuticals, Inc. is a medicine company, which engages in the provision of pharmaceuticals. Its product portfolio includes generics, specialty, biosciences, and product catalog. It operates through the following segments: Generics, Specialty, and AvKARE. The Generics segment relates to oral solids, powders, liquids, sterile injectables, nasal sprays, inhalation and respiratory products, biosimilar products, ophthalmics, films, and transdermal patches and topicals. The Specialty segment refers to the development, promotion, sale, and distribution of proprietary branded pharmaceutical products. The AvKARE segment provides pharmaceuticals, medical, and surgical products and services to governmental agencies. The company was founded by Chirag K. Patel and Chintu Patel in 2002 and is headquartered in Bridgewater, NJ.
Co-FounderMr. Chirag K. Patel
Co-FounderMr. Chintu Patel R.Ph.
Executive VP & CFOMr. Anastasios G. Konidaris
Executive VPMr. Jason B. Daly Esq.
Executive VP & Chief Human Resources OfficerMs. Nikita Shah